Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease

Labandeira-Garcia, Jose L.; Rodriguez-Pallares, Jannette; Rodríguez-Perez, Ana I.; Garrido-Gil, Pablo; Villar-Cheda, Begoña; Valenzuela, Rita; Guerra, Maria J.
December 2012
American Journal of Neurodegenerative Disease;2012, Vol. 1 Issue 3, p226
Academic Journal
The pathogenic mechanism of Parkinson's disease (PD) appears to be multifactorial. However, oxidative stress and neuroinflammation, including activation of NADPH-dependent oxidases, play a major role in the progression of dopaminergic cell death. The renin-angiotensin system (RAS) was described as a circulating humoral system that regulates blood pressure and water homeostasis. However, there exist local RAS in many tissues, and locally formed angiotensin activates NADPH-dependent oxidases, which are a major source of superoxide and are upregulated in major aging-related diseases such as hypertension, diabetes and atherosclerosis. Furthermore, an intracellular or intracrine RAS, with still unknown functions, has been identified in several cell types. The brain has an independent local RAS, which has been involved in several brain disorders, including neurodegenerative diseases. It is particularly interesting for PD the important interaction observed between angiotensin and dopamine, which counterregulate each other in renal cells and also in the striatum and substantia nigra. In recent studies, we have observed both a local and an intracellular RAS in the rodent, monkey and human substantia nigra, and that dopamine depletion induced RAS upregulation possibly as a compensatory mechanism. However, RAS hyperactivation also exacerbated oxidative stress and neuroinflammation, which contributed to progression of dopaminergic degeneration. In addition, we observed increased RAS activity in the nigra of animals with higher vulnerability of dopaminergic neurons to degeneration, such as aged males, menopausal females and rats subjected to chronic brain hypoperfusion. RAS activity and dopaminergic vulnerability were significantly reduced by treatment with angiotensin type I receptor antagonists. Manipulation of the brain RAS may constitute an effective neuroprotective strategy against dopaminergic degeneration in PD.


Related Articles

  • Elevated Homocysteine by Levodopa Is Detrimental to Neurogenesis in Parkinsonian Model. Jin Young Shin; Young-Hwan Ahn; Man-Jeong Paik; Hyun Jung Park; Sohn, Young H.; Lee, Phil Hyu // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Background: Modulation of neurogenesis that acts as an endogenous repair mechanism would have a significant impact on future therapeutic strategies for Parkinson's disease (PD). Several studies demonstrated dopaminergic modulation of neurogenesis in the subventricular zone (SVZ) of the adult...

  • Highlights.  // American Journal of Hypertension;May2011, Vol. 24 Issue 5, p503 

    The article offers information on the research studies related to the therapeutic efficacy of angiotensins in patients with hypertension and early onset-diabetes. A randomized meta-analysis study of renin inhibitor aliskiren and angiotensin receptor blocker (ARB) in blood pressure is presented....

  • Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Kitamura, Noboru; Takahashi, Yasuo; Yamadate, Shuukoh; Asai, Satoshi // Cardiovascular Diabetology;2007, Vol. 6, p26 

    Background: A beneficial effect on glucose metabolism is reported with angiotensin receptor blocker (ARB) treatment of hypertension. The effect on blood glucose level during the course of treatment with ARBs in clinical cases is uncertain. Our objectives were to survey the changes in glucose and...

  • Beyond hypertension: Evidence for use of angiotensin II receptor blockers in renal dysfunction and heart failure. Guillory, Gregory S.; Lynch, J. Christopher // Formulary;Jul2002, Vol. 37 Issue 7, p354 

    Discusses major evidence regarding the potential role of the angiotensin II type I receptor blocker (ARB) in diabetic nephropathy and in heart failure. Pharmacology of the ARB; Comparison of the mechanism of action of the ARB with that of the angiotensin-converting enzyme inhibitor; Results of...

  • Factors Contributing to the Hospitalization of Patients with Congestive Heart Failure. Chin, Marshall H.; Goldman, Lee // American Journal of Public Health;Apr97, Vol. 87 Issue 4, p643 

    Objectives. This study identifies acute precipitants of hospitalization and evaluates utilization of angiotensin--converting enzyme inhibitors in patients admitted with congestive heart failure. Methods. Cross-sectional chart-review study was done of 435 patients admitted nonelectively from...

  • Renin-Guided Treatment of Hypertension: Time for Action. Furberg, Curt D. // American Journal of Hypertension;Sep2010, Vol. 23 Issue 9, p929 

    The author reflects on the treatment of hypertension using Laragh and colleagues study as a guide. According to the author, Laragh and colleagues found out that there are four major types of hypertension including low-renin, medium/high-renin, and resistant hypertension. He says that rennin...

  • Long-term renal prognosis of typical haemolytic-uraemic syndrome suffered in infancy. Martín-Navarro, Juan A.; Petkov-Stoyanov, Vladimir; José Gutiérrez-Sánchez, M.; Justo-Ávila, Pablo; Díaz-Díaz, Delissa // Nefrologia;2013, Vol. 33 Issue 3, p433 

    A case study of a 33-year-old woman who suffered from haemolytic-uraemic syndrome (HUS) and given acute peritoneal dialysis which help in recovering renal functions. Later she was diagnosed with focal segmental hyalinosis by renal biopsy and treated with angiotensin converting enzyme inhibitors...

  • ARBs 'do not lower' AF incidence. Moberly, Tom // GP: General Practitioner;4/24/2009, p12 

    The article offers information on the study conducted on the implication of angiotensin II-receptor blockers (ARB) to hypertensive patients in England. Result reveals that ARB do not reduce incidence of recurrent atrial fibrillation (AF). Moreover, the addition of valsartan to therapies for AF...

  • Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. Baik, Soon Koo; Park, Dong Hun; Kim, Moon Young; Choi, Yeun Jong; Kim, Hyun Soo; Lee, Dong Ki; Kwon, Sang Ok; Kim, Young Ju; Park, Joong Wha; Chang, Sei Jin // Journal of Gastroenterology;2003, Vol. 38 Issue 12, p1150 

    Background Methods. The hepatic venous pressure gradient (HVPG) and portal venous velocity (PVV) were measured both before and 3 months after initiation of the administration of captopril (n = 29) or propranolol (n = 29) in cirrhotic patients with a variceal bleeding episode. Patients who showed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics